Details for Patent: 7,214,696
✉ Email this page to a colleague
Which drugs does patent 7,214,696 protect, and when does it expire?
Patent 7,214,696 protects VYNDAMAX and VYNDAQEL and is included in two NDAs.
This patent has thirty-five patent family members in seventeen countries.
Summary for Patent: 7,214,696
| Title: | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| Abstract: | Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed. |
| Inventor(s): | Kelly; Jeffery W. (LaJolla, CA), Sekijima; Yoshiki (Matsumoto, JP) |
| Assignee: | The Scripps Research Institute (La Jolla, CA) |
| Application Number: | 11/256,026 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,214,696 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,214,696
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) | ⤷ Sign Up | ||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,214,696
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1587821 | ⤷ Sign Up | C300516 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1587821 | ⤷ Sign Up | 91935 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1587821 | ⤷ Sign Up | C20120001 00050 | Estonia | ⤷ Sign Up |
| European Patent Office | 1587821 | ⤷ Sign Up | CA 2012 00006 | Denmark | ⤷ Sign Up |
| European Patent Office | 1587821 | ⤷ Sign Up | 1290005-6 | Sweden | ⤷ Sign Up |
| European Patent Office | 1587821 | ⤷ Sign Up | 12C0008 | France | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
